E
Enlivex Therapeutics Ltd. ENLV
$1.10 $0.065.77% NASDAQ
Recommendation
Prev Close
$1.04
Volume
106,645
Avg Vol (90D)
114,027
Market Cap
$24.60M
Dividend & Yield
--
52-Week Range
$0.8101 - $1.76
P/E (TTM)
--
EPS (TTM)
-$0.7335
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Enlivex Therapeutics files $300M mixed securities shelf
5/2/2025 - TipRanks Financial Blog
Enlivex Therapeutics files $300M mixed securities shelf
5/2/2025 - The Fly
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World ...
4/23/2025 - GuruFocus
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World ...
4/23/2025 - GuruFocus
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress
4/23/2025 - Globe Newswire
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 17.9% in March
4/22/2025 - Zolmax
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Large Drop in Short Interest
4/22/2025 - Ticker Report
Enlivex Therapeutics (NASDAQ:ENLV) Receives "Buy" Rating from D. Boral Capital
4/21/2025 - Ticker Report
Enlivex Completes Phase II Enrollment for Osteoarthritis Trial
4/21/2025 - TipRanks Financial Blog
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
4/21/2025 - Globe Newswire
Enlivex Therapeutics doses first patient in Phase I trial of Allocetra
4/3/2025 - TipRanks Financial Blog
Enlivex Therapeutics doses first patient in Phase I trial of Allocetra
4/3/2025 - The Fly
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
4/3/2025 - Globe Newswire
Enlivex Therapeutics (NASDAQ:ENLV) Issues Earnings Results
4/2/2025 - Ticker Report
Enlivex Therapeutics Releases 2024 Financial Statements
3/31/2025 - TipRanks Financial Blog
HC Wainwright Issues Positive Forecast for Enlivex Therapeutics (NASDAQ:ENLV) Stock Price
3/24/2025 - Ticker Report
Enlivex Therapeutics price target raised to $7 from $6 at H.C. Wainwright
3/24/2025 - TipRanks Financial Blog
Enlivex Therapeutics price target raised by $1 at H.C. Wainwright, here's why
3/24/2025 - The Fly
Enlivex Therapeutics receives notice of allowance for Chinese patent
3/17/2025 - The Fly
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
3/17/2025 - Globe Newswire
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 11.5% in February
3/7/2025 - Ticker Report
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra Trial in Knee Osteoarthritis
3/4/2025 - Globe Newswire
Enlivex Announces Positive Interim Data Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
3/3/2025 - Globe Newswire
Enlivex Therapeutics (NASDAQ:ENLV) Trading 16.5% Higher - Should You Buy?
3/1/2025 - Ticker Report
We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate
3/1/2025 - Simply Wall St
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$14.99M
EBIT (TTM)
-$15.54M
Net Income (TTM)
-$15.01M
Balance Sheet
Total Assets (Q)
$27.69M
Total Debt (Q)
$534.00K
Total Liabilities (Q)
$4.10M
Book Value Per Share (Q)
$0.9974
Cash Flow
Cash from Operations (TTM)
-$13.01M
Cash from Investing (TTM)
$9.06M
Cash from Financing (TTM)
$6.45M
Net Change in Cash (TTM)
$2.51M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Jun 9 and 13 (est)
Price History
Loading...
Beta
1.22
7-Day Total Return
11.73%
30-Day Total Return
7.84%
60-Day Total Return
0.00%
90-Day Total Return
-11.29%
Year to Date Total Return
-11.29%
1-Year Total Return
-29.94%
2-Year Total Return
-63.21%
3-Year Total Return
-74.30%
5-Year Total Return
-79.44%
52-week Low
Nov 21, 2024 - $0.8101
52-week High
Sep 13, 2024 - $1.76
Valuation
Market Cap
$24.60M - Nano Cap
Enterprise Value
$1.64M
Price/Sales (TTM)
--
Price/Book (Q)
1.04
Dividends and Shares
Shares Outstanding
22.49M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.enlivex.com
Phone Number
972 2 670 8072
Address
14 Einstein Street
Ness Ziona, 7403618
Country
Israel
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is... more
NASDAQ 05/06/2025 4:00PM Eastern Quotes delayed